MAIA Biotechnology, Inc. (AMEX: MAIA) is a Healthcare company (Biotechnology) with a market capitalization of $76M. The Maz Rating grades it against the other companies in its sector.
MAIA Biotechnology, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.23, MAIA Biotechnology, Inc. trades at 4.2x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -153.4%, return on invested capital of -176.7% and a free cash flow yield of -40.7%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 3.41. Over the past 52 weeks the share price ranged from $0.87 to $3.19, with a beta of 0.30.
MAIA Biotechnology, Inc. does not currently pay a dividend.
MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, MAIA Biotechnology, Inc. (MAIA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 28.7% / 30% · Interest income / Revenue 18619400.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 28.7% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 18619400.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 28.7% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 18619400.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 96.5% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 18619400.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 96.6% / 33.33% · (Cash+Recv) / Total Assets 96.6% / 33.33% · Interest income / Revenue 18619400.0% / 5% | Fail |
No. As of September 2026, MAIA Biotechnology, Inc. (MAIA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. MAIA Biotechnology, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 18619400.0% of each dividend: MAIA Biotechnology, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.